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Abstract: Type 2 diabetes mellitus (T2DM) is a common chronic disease whose prevalence is currently increasing worldwide. Nowadays, 
the main antidiabetic agent used is metformin. However, between 10 and 30% of patients undergoing metformin therapy have nonspecific 
gastric alterations as an undesired secondary effect. Therefore, the search for new therapeutic alternatives is especially useful, where plant-
derived products emerge as an excellent phytochemical resource. The objective of this review is to present and discuss the state of the art of 
current research conducted on the Berberis gender with hypoglycemic activity, which is normally used in alternative medicine therapy for 
the treatment of T2DM, and its possible mechanisms of action described in literature. 
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Resumen: La diabetes mellitus tipo 2 (DM2) es una enfermedad crónica común, cuya prevalencia está actualmente aumentando en todo el 
mundo. Al presente, el principal fármaco antidiabético utilizado es la metformina. Sin embargo, entre un 10 y 30% de los pacientes tratados 
presentan como efecto no deseado de alteraciones gástricas inespecíficas. Por lo tanto, la búsqueda de nuevas alternativas terapéuticas es de 
gran utilidad, en donde los productos derivados de plantas emergen como un excelente recurso fitoquímico. El objetivo de esta revisión es 
presentar y discutir sobre el estado del arte de investigaciones realizadas en las especies del género Berberis con actividad hipoglicemiante, 
las cuales son normalmente utilizadas en medicina alternativa como terapia para el tratamiento de DM, y sus posibles mecanismos de acción 
descritos en la literatura. 
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INTRODUCTION
Diabetes mellitus is a chronic disease that currently 
affects more than 6% of the world population, with a 
prevalence dramatically increasing worldwide (Shaw 
et al., 2010). Type 2 Diabetes Mellitus (T2DM) is the 
most common clinical form of diabetes, accounting 
for approximately 90% of cases. Currently, it is 
considered a worldwide epidemic since its prevalence 
has tripled over the last 30 years (Chen et al., 2011). 
Because of the complications and the increased 
mortality rate, T2DM is a considerably debilitating 
disease for patients, carrying also a high economic 
cost to society. In view of the prevalence and the 
rapid growth of this important health problem, 
T2DM-related investigation along with the pursuit of 
efficient and safe strategies for preventing and 
treating this disease are of great importance, both 
from an economic and an ethical point of view 
(Nolan et al., 2011). Currently, metformin is widely 
used for the treatment of diabetes. However, 10-30% 
of treated patients have nonspecific gastrointestinal 
alterations (Olivera-González et al., 2010). 
Therefore, the search for new compounds with anti-
diabetic effect is highly required (Verspohl, 2002). 
Plants have always been a good source of drugs and 
many medications available today are derived 
directly or indirectly from them. Existing 
ethnobotanical information suggests that about 800 
plants may possess anti-diabetic potential, evaluated 
by different experimental techniques (Patel et al., 
2012). Studies on Berberis species (Berberidaceae) 
have shown the importance of this genus and its 
potential application in the pharmacological field. 
The Berberis genus is composed globally of 
approximately 500 species, with nearly 300 species 
distributed in Eurasia and about 200 species in 
America (Ahrendt, 1961). This genus holds great 
value in traditional medicine, as it has been generally 
used as a herbal medicine for a long time (Potdar et 
al., 2012), mainly by natives of Asian countries e.g. 
India, Pakistan and China. The objective of this 
review is to present and discuss the knowledge of the 
species of the Berberis genus with hypoglycemic 
activity, currently used as therapy for the treatment of 
diabetes and its possible mechanisms of action 
described in literature. 
 
Berberis lycium Royle 
B. lycium is an evergreen shrub that grows in the 
Himalayan region. Various parts of the plant (root, 
bark, stem, leaf and fruit) have been used by the 
natives of this area as a source of food, feed, fuel and 
medicine (Bano et al., 2013). This plant is widely 
accepted as a medicine due to its therapeutic value in 
India´s Ayurvedic medicine (Sood et al., 2013) (Shah 
et al., 2012) and also as a medicinal plant in Pakistan 
(Ahmad et al., 2009b; Ahmad et al., 2011; Sharma & 
Devi, 2013) mainly used to prevent liver disorders, 
throat infections and asthma, among others (Ahmad 
et al., 2011). Several studies support the function of 
B. lycium as a remedy for diabetes by traditional 
medicine in India and Pakistan (Arshad & Ahmad, 
2005; Ur-Rehman, 2006; Rana et al., 2010; Tiwari et 
al., 2010; Joseph & Jini, 2011; Khan et al., 2013; 
Gilani et al., 2014). Folk´s medicine recipe for the 
treatment of this condition suggest that "the root 
powder (2.5 g) is given twice a day, early in the 
morning and evening after meals for three months" 
(Rana et al., 2010) or that the "shredded bark is 
soaked into water and the resulting extract is drank in 
the morning" (Ahmed et al., 2013). In recent years, 
pharmacological studies show that the extract of B. 
lycium reduces hyperglycemia, producing an insulin-
like effect, which is suggested as a possible 
mechanism of the anti-diabetic activity of the extract 
(Shabbir et al., 2012). Thus, its biological activity has 
been validated by using animal models, mainly 
normal and diabetic rabbits, showing that the use of 
the B. lycium extract reduces blood glucose 
concentration (Ahmad et al., 2009a), as also in 
alloxan-induced diabetic rats (Gulfraz et al., 2007; 
Mustafa et al., 2011; Akram, 2013; Sharma & Sidhu, 
2014). Using the same animal model, it was reported 
that both the fruit extract (Rahimi-Madiseh et al., 
2014), and the root extract (Mustafa et al., 2011), 
improve the lipid profile and may be efficiently used 
as lipid-lowering therapy, especially in diabetic 
patients. In addition, existing reports indicate that the 
extract has anti-glycation and anti-oxidant properties, 
which would decelerate and reduce the aging rate and 
may have a potential role in the treatment of diabetes 
(Khan et al., 2014). The major phytochemicals 
components of the B. lycium root are alkaloids, 
tannins and saponins (Rahaman et al., 2013). Also, 
additional components have been isolated e.g. 
berberine (Figure 1a) berbamine (Figure 1b), 
karakoramine (Figure 1c), palmatine (Figure 1d), 
balauchistanamine (Figure 1e), gilgitine (Figure 1f), 
jhelumine (Figure 1g), punjabine (Figure 1h), 
sindamine (Figure 1i), maleic acid (Figure 1j) and 
ascorbic acid (Figure 1k) (Sood et al., 2013).
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Figure 1 
Chemical constituents isolated from Berberis lycium. a) Berberine, b) Berbamine, c) Karakoramine,  
d) Palmatine, e) Balauchistanamine, f) Gilgitine, g) Jhelumine, h) Punjabine, i) Sindamine, j) Maleic acid and 
k) Ascorbic acid. 
 
Currently, berberine has shown to have antidiabetic 
properties (Lee et al., 2006), principally in the root 
(Gulfraz et al., 2006). However, B. lycium was 
comparable in efficacy to berberine, because the 
plant extract caused a significant reduction of blood 
glucose level and showed important and positive 
effects on glycated hemoglobin, glucose tolerance, 
lipid profile and body weight in alloxan-induced 
diabetic rats (Gulfraz et al., 2008). 
 
Berberis aristata DC. 
B. aristata is a native plant found in temperate 
regions of the northwest of the Himalayas, in the 
Nilgiri and Garhwal mountains and Parasnath hills, 
within an altitude of 1.800 to 2.400 m (Andola et al., 
2010). Several studies have reported this plant as a 
remedy for diabetes in traditional Indian medicine 
(Chauhan et al., 2010; Malvi et al., 2011; Pradhan, 
2011; Kumar et al., 2012; Saravanamuttu & 
Sudarsanam, 2012; Upadhyay et al., 2012; Behera & 
Yadav, 2013; Gupta et al., 2013; Peesa, 2013; Rathi 
et al., 2013; Rawat et al., 2013; Shafi & Tabassum, 
2013; Gupta & Joshi, 2014; Tamilselvi et al., 2014) 
and as part of ayurvedic polyherbal formulations 
(Yadav et al., 2007; Sharma et al., 2010; Kabilan et 
al., 2013; Bordoloi & Dutta, 2014; Mittal et al., 
2014).  
 This plant has an old use as an antidiabetic 
agent by traditional healers of Sikkim (northeastern 
state of India) and the Himalayan Darjeeling region. 
In these tribal villages, bark extract is drank from the 
root of the plant (5-10 ml) twice a day for 1 or 2 
weeks (Chhetri et al., 2005). Moreover, scientific 
reports suggest that B. aristata is in fact an herbal 
remedy with a potent antidiabetic activity (Dixit & 
Mittal, 2013) significantly decreasing blood glucose 
in streptozotocin-induced diabetic rats, with results 
comparable to metformin (Rameshwar et al., 2009; 
Pareek & Suthar, 2010). In the same animal model, 
besides producing an anti-diabetic effect, B. aristata 
extract also markedly decreased total cholesterol 
(TC) and increased high-density lipoproteins (HDL) 
when compared to diabetic controls (Ahamad et al., 
2012). Furthermore, in alloxan-induced diabetic rats, 
the extract of B. aristata has antidiabetic potential, 
reducing blood glucose levels by 60.4% and 75.46% 
using doses of 25 mg/kg and 50 mg/kg, respectively 
(Semwal et al., 2008), as well as reducing TC and 
triglycerides in a dose-dependent manner using both 
bark (Gupta et al., 2010; Ahmad et al., 2012) and 
root extracts (Mittal et al., 2012). Similarly, its 
hypoglycemic effect has been replicated in normal 
and diabetic rabbits, reducing blood glucose at 2, 4 
and 8 hours following treatment with aqueous and 
methanolic extracts of B. aristata (Akhtar et al., 
2008). Effectiveness of B. aristata in regulating 
diabetes can be explained since this plant has the 
ability to inhibit the activity of dipeptidyl peptidase 
IV (DPP-IV), which is responsible for degrading the 
glucagon-like peptide 1 (GLP-1), which is the 
antidiabetic incretin (Chakrabarti et al., 2011). It has 
also been reported that this extract improves glucose 
tolerance and homeostasis (Chan et al., 2012), by 
activating antioxidant enzymes (catalase, superoxide 
dismutase, glutathione peroxidase and glutathione 
reductase) being able to significantly reduce lipid 
peroxidation (41.6%) and protein carbonylation 
(30.15%). It also increases the activity of glucokinase 
and glucose-6-phosphate dehydrogenase besides 
reducing the activity of glucose 6-phosphatase, which 
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plays a critical role in glucose homeostasis in diabetic 
rats (Singh & Kakkar, 2009; Wang et al., 2013). 
 The phytoconstituents present in the root of 
B. aristata are carbohydrates, alkaloids, tannins, 
phytosterols, flavonoids, volatile oils, oils and fats 
(Mittal et al., 2012; Ranjan et al., 2012). The 
compounds isolated from different parts of B. 
aristata correspond to alkaloids as palmatine (Figure 
1d), karachine (2a) palmatine chloride (Figure 2b), 
tetrahydropalmatine (Figure 2c) pseudopalmatine 
chloride (Figure 2d), oxyberberine (Figure 2e), 
taxilamine (Figure 2f), pakistanine (Figure 2g), 1-O-
Methyl pakistanine (Figure 2h), Oxycanthine (Figure 
2i) berbamine (Figure 1b) and aromoline (Figure 2j). 
Flavonoids such as quercetin (Figure 2k), meratin 
(Figure 2l) and rutin (Figure 2m); and chlorogenic 
acid (Figure 2n) and (E)-caffeic acid (Figure 2o) 
(Potdar et al., 2012). Among alkaloids with 
antidiabetic activity we can find berberine (Figure 
1a), columbamine (Figure 2p) and jatrorrhizine 
(Figure 2q) (Osadebe et al., 2014). 
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Figure 2 
Chemical constituents isolated from Berberis aristata. a) Karachine, b) Palmatine chloride, c) 
Tetrahydropalmatine, d) Pseudopalmatine chloride, e) Oxyberberine, f) Taxilamine, g) Pakistanine, h) 1-o-
methylpakistamine, i) Oxycanthine, j) Aromoline, k) Quercetin l) Meratin, m) Rutin, n) Chlorogenic acid,  
o) (E)-Caffeic acid, p) Columbamine and q) Jatrorrhizine. 
 
Berberis asiatica Roxb. Ex. DC.  
B. asiatica is a thorny evergreen shrub reaching 1.8 
to 2.4 m of height, and located at an altitude between 
600-2550 m in the Himalayas (Patni et al., 2012), 
used in traditional Indian medicine (Balami, 2004; 
Kala, 2005; Jain et al., 2006; Joshi & Joshi, 2007; 
Kunwar et al., 2008; Kunwar & Bussmann, 2009; 
Joshi et al., 2010; Pala et al., 2010; Joshi & Tyagi, 
2011a; Joshi et al., 2011b; Kumari et al., 2011; Singh 
et al., 2012; Thapa, 2012; Kunwar et al., 2013; 
Radha et al., 2013; Sigdel et al., 2013) primarily for 
the treatment of muscle pain, toothache, stomach 
illness in animals, rheumatism and dental care 
(Shrestha & Dhillion, 2003) and also used as an 
antipyretic, anesthetic, antihypertensive and for the 
treatment of conjunctivitis (Uprety et al., 2010). At 
present, it is used to combat some female pathologies 
such as menorrhagia and leucorrhea and as a special 
preparation for the treatment of poor lactation 
(Ghildiyal et al., 2014). Moreover, in Bangladesh, 
Indian traditional medicine specialists are known for 
making up preparations from medicinal plants for the 
treatment of diabetes mellitus, including B. asiatica 
as a recognized alternative medicine product 
(Rahman et al., 2009; Singh et al., 2014). Research in 
rats indicate that the root extract of B. asiatica 
presents a very strong and even greater antidiabetic 
activity than obtained by glibenclamide (Singh & 
Jain, 2010b). Hypoglycemic activity in rats was also 
reported, however, at the studied concentration, no 
significant effect was observed when compared to B. 
aristata, suggesting that B. asiatica should be applied 
in higher doses (Upadhyay et al., 2012). The 
phytochemical constituents that are part of the root 
and stem are tannins, flavonoids, alkaloids, steroids, 
saponins, phenols, carbohydrates, proteins and free 
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amino acids, while glycosides are absent in both 
structures (Patni et al., 2012,).  
 From the root of B. asiatica have been 
isolated alkaloidal compounds such as berberine 
(Figure 1a), palmatine (Figure 1d), jatrorrihizine 
(Figure 2o), columbamine (Figure 2n), 
tetrahydropalmatine (Figure 2c), berbamine (Figure 
1b), oxyberberine (Figure 2e) and oxycanthine 
(Figure2i) (Bhakuni et al., 1968), being berberine the 
main compound to which has been attributed the 
pharmacological potential observed, and reporting 
that greater amounts are found in plants located at 
lower altitudes (Maithani et al., 2014). 
 
Berberis vulgaris Linn.  
B. vulgaris is a common shrub in Europe, Asia, 
Africa and some northeast regions of the United 
States. Its use in traditional medicine dates back more 
than 2.500 years in Ayurvedic and Chinese medicine 
as a treatment for fever and gastrointestinal disorders. 
In Iran, it is used as an antibacterial, antipyretic, 
antipruritic and antiarrhythmic agent (Brenyo & 
Aktas, 2014). In India, B. vulgaris is prescribed for 
patients suffering kidney and urinary problems and 
gallstones-related pain (Joshi & Joshi, 2013). In 
Turkey, the fruit is used to combat intestinal worms 
and for hepatoprotection (Tetik et al., 2013) as well 
as to counteract diabetes mellitus (Altundag & 
Ozturk, 2011).  
 It has also been reported that the aqueous 
extract of the root and the crude saponin extract of 
this plant significantly reduce the concentration of 
blood glucose besides improving the lipid profile in 
streptozotocin-diabetic rats (Meliani et al., 2011; 
Arumugam et al., 2013). This hypoglycemic effect of 
the saponins from the B. vulgaris root may be due to 
the stimulating effect of the remaining beta cells 
(Saravanamuttu & Sudarsanam, 2012). Another 
possible mechanism that could explain the 
hypoglycemic effect could be because of the 
inhibition of the activity of the enzyme α-
glucosidase, which would result in decreased 
carbohydrate absorption and the suppression of 
postprandial hyperglycemia, contributing to reduced 
hemoglobin A1c (HbA1c) (Abd El-Wahab et al., 
2013). It was also determined that the root extract of 
B. vulgaris was able to reduce alanine 
aminotransferase (Altundag & Ozturk., 2011) and 
alkaline phosphatase activities, reasons for which the 
extract would have important properties to improve 
hepatic function (Taheri et al., 2012). However, 
despite all positive reports for diabetes treatment, at 
concentrations of 3.5% and 7.5% (v/v), the aqueous 
fruit extract of B. vulgaris do not possess 
hypoglycemic or hypolipidemic activity in 
streptozotocin-diabetic rats during a treatment period 
of 6 weeks (Hajzadeh et al., 2011), which would 
pinpoint the necessity to continue further research in 
order to corroborate accurately the benefits of using 
this plant. The roots of B. vulgaris are formed by 
alkaloids, flavonoids, saponins, phenolic content, 
cardiac glycosides and terpenoids (El Sayed et al., 
2011; Meliani et al., 2011; Abd El-Wahab et al., 
2013). In the root, chemical percentages are as 
follow: 2.6 to 4% alkaloids, 1.9 to 4.9% flavonoids 
and 0.3 to 0.35% saponins (El Sayed et al., 2011; 
Abd El-Wahab et al., 2013). Several alkaloids have 
been isolated from this plant, such as aromoline 
(Figure 2h), berbamine (Figure 1b), berberine (Figure 
1a), berlambine (Figure 3a), columbamine (Figure 
2n), hydroxycanthine (Figure 3b) isocorydine (Figure 
3c), oxyberberine (Figure 2e), oxycanthine (Figure 
2i), palmatine (Figure 1d), (-) - tejedine (Figure 3d) 
and jatrorrhizine (2o) (El Sayed et al., 2011; Abd El-
Wahab et al., 2013; Mokhber-Dezfuli et al., 2014), 
and only 2 compounds quercetin (Figure 2i) and rutin 
(Figure 2k)- are among the isolated flavonoids (El 
Sayed et al., 2011; Abd El-Wahab et al., 2013). The 
terpenoides, lupeol (Figure 3e) and oleanolic acid 
(Figure 3f) and the steroids stigmasterol (Figure 3g) 
and stigmasterol glucoside (3h) (Saied & Begum, 
2004; Mokhber-Dezfuli et al., 2014). 
 Regarding the active component 
concentration –berberine- it is mainly found in the 
bark (6%), followed by root (3.8%) and the lowest 
concentration is detected in leaves and fruits (1.29 
and 1.18%, respectively) (Hadaruga et al., 2010). 
 
Berberis integerrima Bunge 
B. integerrima is an ethnobotanical species located in 
the Middle East (Rajaei & Mohamadi, 2012; Nasab 
& Khosravi, 2014). It is currently used as a medicinal 
plant in the region of Alamut (Ghazvin Province) 
northeast of Iran. Here, infusions or food preparations 
are meant to treat enteric fever, hyperlipidemia, 
diabetes and anemia (Ahvazi et al., 2012). Likewise, 
it is used as nourishment in the villages of the Ilica 
district in Turkey (Özgen et al., 2004) and to treat 
hemorrhoids (Özgen et al., 2012). There have been 
several reports describing the hypoglycemic potential 
of the B. integerrima extract in streptozotocin-
induced diabetic rats, where studies using the 
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aqueous extract of the root have exhibited 
antihyperglycemic, antihyperlipidemic and 
antioxidant activities (Ashraf et al., 2013c) by 
increasing insulin secretion and enhanced growth of 
the diameter and number of pancreatic islets of 
Langerhans (Ashraf et al., 2013d). Therefore, B. 
integerrima possess a therapeutic and preventing role 
against diabetes mellitus (Ashraf et al., 2012), along 
with the capability of protecting renal (Ashraf et al., 
2013b), and hepatic (Ashraf, 2014) tissues, and 
restoring diabetes-induced damage in testis along 
with improving testosterone levels (Ashraf et al., 
2013a). However, in a report made using the aqueous 
extract of the fruit, it is argued that this would not 
exercise any hypoglycemic or lipid-lowering effect, 
suggesting that the response to the extract is 
conditioned by both time and dose exposure (Ashraf 
et al., 2014). 
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Figure 3 
Chemical constituents from Berberis vulgaris. a) Berlambine, b) Hydroxycanthine, c) Isocorydine,  
d) (-) Tejedine, e) Lupeol, f) Oleanolic acid, g) Steroids stigmasterol and h) Stigmasterol glucoside. 
 
Berberis ceratophylla G.  
B. ceratophylla is a species used as a natural 
medicine in the villages of the Middle East (Yavari & 
Shahgolzari, 2010) to treat diabetes and hepatitis 
(Ummara et al., 2013). In India, it is also used as a 
antidiabetic treatment (Rani et al., 2013). 
Nonetheless, poor information exists regarding its 
power as a hypoglycemic agent in current literature. 
 
 
Berberis moranensis Schult. & Schult. 
At present, in Mexico there are more than 500 
species being utilized in traditional medicine to 
counteract diabetes (Jarald et al., 2008). Among 
these, B. moranensis is a prominently used 
hypoglycemic agent (Andrade-Cetto & Heinrich, 
2005), but no further information was found 
regarding its glucose-lowering effect. 
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Berberis crataegina DC 
It is a traditional medicinal plant found in Turkey´s 
Middle East, presently used to treat diabetes 
(Karaman & Kocabas, 2001) by both the fruit and the 
root (Altundag & Ozturk, 2011). Among the 
alkaloids isolated from this plant, is highlighted the 
presence of berberine (Figure 1a) and palmatine 
(Figure 1e) which predominate in all organs 
excepting the seed (Petcu, 1968). 
 
Alkaloids responsible for hypoglycemic activity 
The high content of alkaloids present in the different 
species of Berberis would be responsible for 
exercising its hypoglycemic activity. In current 
literature, three alkaloidal compounds are 
emphasized to have this biological potential: 
Berberine 
Berberine has been defined as a potential drug 
because of its several pharmacological properties 
(Singh et al., 2010a). Early studies with berberine 
arise from 1986. Since then, berberine was 
introduced as an alternative medicine for the 
treatment of diabetes in Asian countries (Yin et al., 
2012). At present, investigations have focused on 
determining the action mechanisms of berberine e.g. 
glucose and lipid metabolism, AMPK and 
mitochondrial function activation, liver, pancreas and 
intestine regulation and antioxidant activity (Yin et 
al., 2012). Table one shows the main described 
mechanisms and study models used. 
 
Table 1 
Antidiabetic mechanisms described for berberine. 
Study model Action mechanism 
DM2 patients Decreased levels of free fatty acids in serum (Gu et al., 2010). 
Cell lines: CEM, HCT-116, 
HepG2.2.15, SW1990, 
HT1080 y 293T. 
Increased gene expression of the insulin receptor (Zhang et al., 
2010). 
Diabetic rats Direct inhibition of liver gluconeogenesis (Xia et al., 2011). 
Cell line L929 Activation of GLUT 1 transporter (Cok et al., 2011). 
Cell lines 3T3-L1 y L6 Inhibition of the phosphatase activity of protein tyrosine 
phosphatase 1B (PTP1B), and increased IR and IRS1 
phosphorylation (Chen et al., 2010). 
DM2 patients AMPK pathway stimulation and insulin receptor expression 
induction (Di Pierro et al., 2012). 
Diabetic rats Improved oxidant-antioxidant balance by increased mRNA 
expression of hepatic superoxide dismutase (Chatuphonprasert et 
al., 2014). 
Diabetic rats Intestinal microbiome modulation (Han et al., 2011). 
Diabetic rats Lipid metabolism regulation and increased elimination of free 
radicals (Tang et al., 2006). 
Diabetic rats Down-regulation of lipogenic genes and up-regulation of genes 
involved in energy transfer in fatty and muscle tissues (Lee et al., 
2006). 
Cell lines L6 and LKB1−/− AMPK activation, by complex I inhibition of the mitochondrial 
transport chain (Turner et al., 2008). 
Diabetic rats PPAR α/δ up-regulation and PPARδ repression in liver (Zhou et 
al., 2008). 
Non-obese diabetic rat Regulation of MAPK activity to control the differentiation of 
Th17 and Th1 (Cui et al., 2009). 
Diabetic rats Promotes secretion of glucagon-like peptide type I (Lu et al., 
2009). 
Diabetic rats Tyrosine phosphatase 1B activity inhibition and insulin-like effect 
(Chen et al., 2010). 
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Cell line 3T3-L1 Decreased triglyceride accumulation by improving pIRS1-PI3K-
pAkt, GLUT4 translocation and greater insulin tropic action by 
pCREB-pIRS2-pAkt (Ko et al., 2005). 
Diabetic hamster Up-regulation of LXR y PPARα, and down-regulation of SREBPs 
(Liu et al., 2009). 
Cell line L6 Enhanced AMPK and p38 MAPK phosphorylation (Cheng et al., 
2006). 
Cell line 3T3-L1 Regulation of PPARs and positive transcription elongation of 
factor b expression (Zhou & Zhou, 2010). 
Diabetic rats Decreased activity of intestinal disaccharidases and b-
glucuronidases (Liu et al., 2008). 
Diabetic rats Glucose metabolism modulation by GnRH-GLP-1 and MAPK 
pathway in the gut (Zhang et al., 2014). 
Cell lines HepG2 and C2C12 Enhanced glucose metabolism by glycolysis stimulation and  
mitochondrial respiratory chain inhibition (complex I) (Xu et al., 
2014). 
Cell line HL-7702, normal 
human liver cell lines  
LDLR up-regulation by AMPK-dependent Raf-1 activation (Li et 
al., 2014). 
 
Jatrorrihizine 
Another alkaloid with important hypoglycemic 
activity is jatrorrihizine. This compound causes a 
pronounced decrease in blood glucose in both normal 
and hyperglycemic mice, which could be attributed to 
improved aerobic glycolysis (Yan et al., 2005). 
However, when comparing the response obtained by 
jatrorrihizine vs. berberine in reducing blood glucose 
in mice, jatrorrihizine showed has a lower response to 
the same dose investigated (Fu et al., 2005). 
 
Palmatine 
The hypoglycemic activity of palmatine has been 
explored since this compound lowers blood glucose 
concentration in normal rats (Patel & Mishra, 2011), 
and anti-diabetic activity may be mediated through 
insulin dependent pathway by the activation of IRTK 
and PI3K (Sangeetha et al., 2013). 
 
CONCLUSION 
Different Berberis species exhibit hypoglycemic 
potential, being probably responsible for this activity 
the alkaloidal compounds, as they can modulate 
glucose metabolism through multiple mechanisms. 
However, we emphasize the need to continue further 
research along with performing toxicological tests, to 
avoid side effects risks associated to herbal medicine 
therapy. In addition, the Berberis genus presents a 
unique and great potential of study, not only as 
hypoglycemic agent but also as a diverse therapeutic 
product, generating the opportunity to explore 
different research lines related to the biological 
activity of this significant bio-resource. 
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